IceCure Medical Ltd. (NASDAQ:ICCM) Stock Short Interest Report for September

IceCure Medical Ltd. (NASDAQ:ICCM) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 52,159 shares, a drop of 49.2% from the September 15th total of 102,639 shares. Based on an average daily trading volume, of 123,547 shares, the short-interest ratio is presently 0.4 days. Currently, 1.6% of the company’s shares are sold short.

IceCure Medical Trading Down 8.2%

ICCM traded down $0.09 during trading on Wednesday, reaching $1.01. 102,720 shares of the company’s stock were exchanged, compared to its average volume of 1,094,949. The stock has a market capitalization of $3.46 million, a PE ratio of -0.12 and a beta of 0.43. IceCure Medical has a one year low of $1.01 and a one year high of $26.97. The firm has a fifty day moving average price of $2.15 and a two-hundred day moving average price of $4.86.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. The business had revenue of $0.91 million for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%. Sell-side analysts expect that IceCure Medical will post -4.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ICCM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Wall Street Zen lowered IceCure Medical from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Finally, Zacks Research raised shares of IceCure Medical from a “strong sell” rating to a “hold” rating in a research report on Monday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, IceCure Medical presently has an average rating of “Hold” and an average target price of $30.00.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is an Israel-based medical technology company that develops minimally invasive cryoablation systems for the treatment of tumors. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to surgical removal in selected patients.

The company’s primary product is the ProSense system, which is designed to deliver controlled cryoablation through a probe inserted into a tumor. IceCure has focused on applications in breast, kidney, lung, and other solid tumors, including procedures performed under image guidance.